Yet Another Value Podcast - Random Ramblings April 2025

Starting point is 00:00:00 Today's podcast is sponsored by DeLUPA. Are you ready to cut through the noise in AI and discover the real impact it's having in financial services? Join me alongside Thomas Lee, the CEO of Delupa on April 15th at 1 p.m. Eastern for an exclusive webinar where we'll dive deep into the future of AI tooling and finance. We've all heard the hype, but what's the truth behind the tech? We'll discuss how AI is transforming financial workflows and where it's actually delivering value. With Thomas' experience leading a fundamental data company that leverages AI, you'll get firsthand insights into what works and what doesn't in this space. Whether you're managing a hedge fund, analyzing financial data, or simply interested in how AI is shaping the future of finance, this webinar is for you.

Starting point is 00:00:41 Don't miss out on valuable insights from industry leaders. Register now at dilupa.com slash y-A-V webinar. That's the l-O-O-O-P-A dot com slash y-A-V webinar for the April 15th, 1 p.m. Eastern webinar. and get ready to uncover the truth about AI and finance. All right, hello, and welcome to the yet another value podcast. I'm your host, Andrew Walker. It's great to have you here with me today. I'm happy to have on myself as my guests for my monthly random ramblings.

Starting point is 00:01:11 It is just before market closes on April 11th, and that's a Friday. I normally do my random ramblings. I take a Saturday morning to them, but as I'll discuss, I'm going on one of the worst-timed vacations and work trips over the next. two weeks in the history of the world. So I didn't have time for that on Saturday. I'll dive into that more later. But before we get there, quick disclaimer, remind everyone, nothing of this podcast is investing advice. I'll include a link to my disclaimer in the show notes. There's another disclaimer at the end of the episode so you can hear all that, not financial advice. Let's dive

Starting point is 00:01:43 into it. Look, it has been a wild, wild ride this week. You've had tariffs, no tariffs, the best day in stock market history on Wednesday, some of the worst days in stock market history last week earlier this week, blah, blah, blah, blah. I'll talk about all that in a second. First thing I want to start talking about is KEROs. The ticker is KROS. I am Longing. This is the last podcast I did.

Starting point is 00:02:03 I published it on Wednesday. It was very, very well-time because I published a podcast on Wednesday saying, hey, KRS, you're trading for a huge discount to cash. You need to wind this up. Or I think you need to do what's right for shareholders. What's right for shareholders, in my opinion, is to wind it up. I think I presented very compelling evidence why that was the most compelling thing to do. and I encourage shareholders to whether they agreed with me or not,

Starting point is 00:02:25 reach out to the board and tell them to do that. On Thursday, KRS came out and said, hey, we're evaluating strategic alternatives. We're going to provide an update on the strategic alternatives process in the next 60 days, and the stock was up a lot. It went from $10 to, as I'm recording this, about $12 per share. Which do I prefer the stock at $12 versus $10 per share? Yeah, I don't mind that, Mark, I will say.

Starting point is 00:02:49 But here's a few things that are interesting. I think it speaks to how bombed out and how mistrusting investors are that KRRS announces we're reviewing strategic alternatives and the stock goes from 10 to 12. Yes, that is a nice move. Guys, this company has $16 to $18 per share and net cash on their balance sheet and at least one other asset that I think is clearly NPV positive in the royalties that they are owed from Takeda. So yes, the mark is up, but it speaks to how bombed out and mistrusting the sector is that

Starting point is 00:03:20 the company announces strategic alternatives, says, hey, we had someone, it was not me, I can assure you that, I wish it was me. We had someone acquire over 11% of the stock. In response to that, we're doing a strategic review, and the stock went from 50% of net cash to 60% of net cash, right? So I say this because a lot of you might have listened to this on Thursday morning and thought, oh, I missed it. The company announced strategic alternatives. In my opinion, I'm talking my own book. I'm along the stock. The answer is no. You did not miss it. This is still a corporate governance play. The market is still hugely skeptical that KROS is going to do the right thing.

Starting point is 00:03:56 If the market had no skepticism, this stock would be trading for. Reasonable, people can disagree if the answer is 17, 19, 16, 22, this stock would be a lot higher. The market is still really concerned that KROS, again, $18 per shareish of cash, trades for $12. The market is saying, hey, ignore all the other assets. This company is going to turn every dollar they have into $0.66 of cash on the dollar. and it's also going to burn all the other assets, too. So this is still a corporate governance play. You might be thinking, I missed it.

Starting point is 00:04:26 I mean, look, I'm not a financial advisor. I can't tell you if you did it or not. But I'm just saying, I don't think you missed it. And I think it is still absolutely critical that you lob in letters to this board, go contact IR. And whatever you think the right path is, they're in a 60-day review period, say, I believe this is the right path.

Starting point is 00:04:43 You need to show me, if this isn't the right path, you need to show a lot of reasons why, with really compelling evidence, because there's a path here to create shareholder value. It is a very easy one. The market is very skeptical. I am a shareholder. I own this company.

Starting point is 00:04:57 There are some big shareholders in the board, and there are some very small shareholders in the board. The board cannot allow this company to light this much money on fire. You have to rationalize. You have to maximize my shareholder value. So I just want to say that. Let me turn to the next thing. Again, the big focus of my past month, fortunately or unfortunately, this year has been this busted biofarm story. I did the KRS podcast.

Starting point is 00:05:21 I did the SAGE podcast. I'm long sage as well. I've put several articles on the blog. I've got another one coming in the near future. But basically, I mean, it is nuclear winter in the pre-commercial biotech market, right? There are just so many companies. I could show you so many, 300 million cash trading for under 100 million market cap. KROS, 750 million of cash trading for 500 million market cap after they announced strategic alternatives, right?

Starting point is 00:05:48 It is absolute nuclear winter. And I've publicly called up to now, KRS and Sage, and long. On the blog, I've mentioned several more, on the premium side, I've mentioned several more that I am long. On the public side, I've mentioned several more that are interesting, that trade at huge discounts, but for one reason or another, I don't have a position in, right? And when I've done these callouts, I have gotten calls, emails, that sort of stuff, from small shareholders, large shareholders, professional shareholders, who own some people, who own some amount of stock in this company.

Starting point is 00:06:21 And I've talked to them and they'll say, hey, like, they're really encouraging me. They're like, hey, we agree with everything you say. We've owned 4% of this company for two years. And we are just talking to the board behind the scenes every time and saying, hey, rationalize all this sort of stuff, doing all this. And so they're really encouraging me. And then I'll say, hey, great, look, I'm happy to go push these companies. companies for what's right, because I, A, the inefficiency of a company having a 300 million

Starting point is 00:06:51 market cap and 300 million in cash, 100 million market cap, that weighs on me, but also the portfolio returns if I can get them to rationalize it. I love that, right? I'm happy. But when I push them, like, hey, why aren't you being more aggressive? Why aren't you going out and making this publicly known? Why aren't you applying more pressure to the board? And a lot of these guys will say, hey, we don't want to get the activist label. And we've got a business. And we're kind of thinking about our business long term, right? If we go activist on someone, then the next time a company does a pipe round or a private fundraising amount or something, we're not going to get invited because people will be worried to bring us under the tent. And look, I get that. I totally get

Starting point is 00:07:29 that. And I can't tell anyone how to run their business. But I just, you know, I want to put it out there for all investors because, again, I know there are some, not to overtook my own horn, but I do know of some large investors in these pharma companies who have listened to at least the the pitches that I've done. Look, if you own five positions, five biotex, and they're all trading for half of cash, and you're saying I'm not going to go push them to liquidate, to rationalize value because I want to be invited to the next pipe round. What's the point, right? You know what would be better for the next pipe round? If all of your positions had doubled, so you had two X the amount of money, and you could write a bigger check. And when the pipe round comes up, you can say,

Starting point is 00:08:07 hey, yeah, we'd hate to go activist, but look, these guys were trading for 33% of net cash, and they we're going to light it all on fire on silly science projects. You, Mr. Management team, you surely wouldn't do that with my money. So you have no need to worry. So that's point one. And then point number two, every biotech company, every pre-revenue biotech company, is trading for 50% of net cash. What person is going to put a pipe into any company?

Starting point is 00:08:30 Like, if you came with a pipe tomorrow, why would you ever put a pipe? Why would you put fresh money into any company when it's instantly going to trade for 50% of net cash? So I understand people are saying, I need to protect my, I need to. to protect my ability to pipes. I need to protect my ability to mainstream fields. I just say, there is no place where you're putting pipes in this market. Like, let's go rationalize these things and then pipes can be affected in the future. But in this market, nobody's going to do it. So anyway, I'm on a little bit of a rant. I completely understand. I'm not calling anyone out, but I would just say like, hey, if all of these things, if I was pointing out them saying, look,

Starting point is 00:09:05 they've got $10 per share of cash on their balance sheet. They trade for $9.50. You know, I think they should liquidate. I think they've got another $10 of cash and $2 of other assets. I think they should liquidate. And people are coming to me like, hey, we can't do that. We don't want to ruin our relationship with management team. We're thinking about our future deals. I can completely understand that. We're not in that situation. All of these things are $10 per share of cash, trading for $3, $4, $5. This is not about, hey, let's preserve the future. There is no future if these companies don't figure this out. And that's my rant. I just, you know, all of these guys are incredibly smart, but I just keep hearing the same line, hey, we can't get, we can't go

Starting point is 00:09:44 activists, we can't do this. And I'm just a small guy sitting in a closet of a office. I'm happy to push as hard as I can. But I think if you are an investor in one of these companies, particularly larger one, it's time to look and say, hey, this is so existential and the upside is so high. Maybe it's time to get our hands a little dirtier. And look, again, I'm happy to keep getting my hands the 30 as possible, because I think the upside is enormous, and I think these are generational opportunities, but that's just my push that I keep hearing for people. Let me go to the third thing. Let's talk. Let's talk stock. And I think this will tie in well between both the below-cash biotech companies I was just talking about, and I want to end by just

Starting point is 00:10:33 talking about how wild markets have been. But one thing that I've been increasingly thinking about is you know, there's all this conversation on stock, you hear lots of conversations on stock comp. Is it a real expense? Is it the same as cash expense? All that sort of stuff. And, you know, I'm kind of a value investor. I fall into the yes, of course, stock comp is a real expense. But I've been increasingly thinking about, hey, does stock comp make you anti-fragile? And let me give a very simple example. Like, look, stock comp, one of the things you love about is it should create alignment among all parties. But I've been thinking if it creates an anti-fragile company, because imagine this.

Starting point is 00:11:12 Imagine you have a company that's a $400 million market cap company. They spend $10 million per year on stock comp, right? So two and a half percent dilution per year in stock comp. It's all RSUs. You know, they just price them, two and a half percent, no big deal, right? Alignment, all that sort of stuff. Well, imagine the stock gets cut in half, and the stock goes from $400 million to $200 million. I mean, if it gets cut in half because of it.

Starting point is 00:11:38 market turmoil. I know plenty of companies that have been cut in half so far this year, right? Are you going to go to your management team? Are you going to go to your higher level employees or your senior engineers and say, hey, we're going to have to cut your comp in half because our stock's been cut in half because of market turmoil? No, there's no company that's going to do that. The executives have, I mean, they literally have a contract, right? They have a contract. That's how much they get. So the stock gets cut in half, goes to 200, million. And this year, you're paying them $10 million in stock comp still. So now it's 5% dilution. And you can imagine it going in further and further, right? Some of these net cash biofarms that I've

Starting point is 00:12:18 been talking about, this stock has gone down 80% because their lead drug has been proven to be worthless. And all of a sudden, they go from a billion dollar company to a $200 million company when they were a billion dollars and they were spending $30 million per year on stock comp, not a big deal. You're a growth company. You're aligning incentives. All of a sudden, you go to it's $200 million and you're spending $30 million, all of a sudden you're diluting your shareholders 15% per year. And by the way, you know, in all these I'm looking at, they're trading at a $300 million market cap with $600 million in cash. So 15% dilution, 30% dilution if you're kind of looking at it on a, I said it's not 30% dilution on it. But it's a lot

Starting point is 00:12:57 to, you know, you're diluting 15% and you're doing it at half of cash value. Like it's just absolutely insane. So I've just been thinking like, you know, in, a world that, in my opinion, is more volatile going forward. Stock comp, do you need to look at it a little bit more skewed? Because if things get rocky and stocks go down, the company is going to be a lot more more dilutive than you were expecting. So it actually makes the stock anti-fragile. The further it goes down, the less upside there is because the employees are taking more

Starting point is 00:13:31 and more of the comp. I don't have a great answer. Obviously, it's a little bit of a niche case. It relies on stocks going down quite a big. bit and the company, you know, the short term, most of the stock comp is actually pretty locked in. You can change any cost structure over the mediums the longer term, but just something I've been thinking about.

Starting point is 00:13:48 I think it's really interesting, particularly, you know, the biotex, I'm talking about. Most of them get to be net cash because the stock goes down 50, 70, 80 percent. And then let's use that to transition to wild markets, you know. I'm, again, I'm recording this April 11th. You know, I thought March was pretty damn negative in the middle of the month. I was starting to see a lot, I will tell you, I, A, I personally have never felt as outside of maybe COVID as dejected as I was doing kind of last week and earlier this week with the height of the Trump taroffs and the stock market down 5, 5, 5% every day.

Starting point is 00:14:23 And, you know, all of some of the smaller liquid stuff I'm in, it was just crazy. But I will tell you, I've never seen, it's the most bearish I can remember things going. So I just wanted to give a comment. on wild markets. Look, when markets get wild, it is really easy. And I certainly had several days where I was more just staring at the screen. Like I keep a big notes folder of everything I'm researching and reading everything. And my notes holder was a lot more empty than it generally would be. And that's kind of, it's human nature and shame on me, right? But I would tell you, you really have to try when the markets are rocky, whether they're flying high, choppy,

Starting point is 00:15:04 going down, you really have to try to kind of keep the same methodology, the same system, the same practice every day. I'll give you a few reasons why. Number one, markets are rocky, right? I had two days there where I wasn't going to allow them. You're kind of two days behind on research. And if you think about the compounding, it's not great to skip a couple days of research. But the other thing is, if you stick to that process and you're reevaluating, I think it's easier to spot opportunities. I'll give you an example. You know, oh, Well, let's talk opportunity a second. I also think you need to be re-evaluating your portfolio in real time.

Starting point is 00:15:38 You know, if you came to me and said, hey, Andrew, my portfolio today, right now, April 11th, is the exact same as my portfolio was April 11th, 2004, right? I would say, hey, man, that's great. You're convicted. You've got conviction. You've done a lot of research on your projects. If you're the exact same, I don't really think you're evaluating opportunity costs, right? Like your portfolio should always be your risk-adjusted best. set of ideas. And then obviously there are concentration, diversity implications and all that

Starting point is 00:16:08 your stuff. But it should always really be your best set of ideas. And if you told me my best set of ideas today is the exact same as it was and the exact same sizing as it was one year ago, I'd say you're probably not turning over enough rocks. You're probably not updating your priors enough. You're probably not thinking through it enough. So I think if you're continuing to research, there are a lot of benefits. And one is you can see in real time, right? If I've got this 10 company portfolio and I research a new company, I can see in real time, like what are some of the other opportunities out there? And sometimes it'll hit me where I'm researching a new company and I'll say, oh my God, this is great. And then I'll look at a

Starting point is 00:16:47 company in my portfolio that I thought was a good risk reward. I'd be like, hey, this company I own, you know, it trades at 10. I think the downside's 5. I think the upside's 20. This new company I'm researching it trades at 10. I think the downside is 8 and I think the upside's 30. So now I can say, hey, I'm seeing better risk rewards in the market. It's time to swap, right? And if you're seeing that a lot, then it's, hey, your whole portfolio might be too stale. But the second reason I think it's interesting to do is you can spot really interesting opportunities.

Starting point is 00:17:15 And I'll give you one in volatile changing environments. And I'll just give you one quick example of one that's been on my mind. Tariffs, right? They're clearly going to be tariff winners and losers. I think it's going to be a lot of losers. I think it's more likely to harm the economy on the whole. But you could imagine a company that is, you know, there's a lot of businesses that are natural monopolies or oligoplies, right, because of distance. You know, you think a value investor favorite is cement.

Starting point is 00:17:53 Cement naturally concentrates into a few local hands because it is very heavy, right? So it's very expensive to transport. So when you build a cement plant, all of your sales tend to be, and I'm simplifying a little bit, all of your sales tend to be within a 10, 20, 50 mile radius, whatever it is. You're not going to build a cement plant in southern Florida and be able to fill cement orders in northern Portland, right? It's only going to be Florida, so it tends to be really local market. I could imagine a scenario where you have a cement plant, you know, 20 minutes south of the Canadian border,

Starting point is 00:18:28 and then you have a cement plant five minutes north of the Canadian border. And before all the tariffs go in place, the cement plant five minutes north of the Canadian border would service anyone that was, you know, right on the other side of the Canadian border. So they're six minutes away, right? Six minutes away from the Canadian plant, 20 minutes away or 19 minutes away from the U.S. plant. That's a big transportation cost. I could imagine that all of that cement service is getting filled by the Canadian plant.

Starting point is 00:18:54 And again, I'm simplifying here everything, right? I don't know the time, the distance, everything. I'm just simple fine. But you slop a 10 or 25% tariff on the stuff that's coming from Canada, and you could imagine that all of a sudden maybe the U.S. plant is better equipped. It's lower cost for them to serve all of those towns close to all those towns close to the border that are on kind of the domestic side of the border. And maybe it's not better for them to serve the ones that are right on the other side of border.

Starting point is 00:19:21 But at some point, I would guess there are some towns that were previously getting served better by the Canadian company that because of tariffs are better served by the U.S. company. And what does that mean? That means that U.S. company better utilization. They're probably going to have a little bit better pricing. You know, you could imagine there were some towns that were right in the middle, where before every year they put up their pricing and it would be a big battle between the U.S. and the Canadian company, and they basically price each other kind of to the marginal cost of capacity. Well, guess what? Now all of that capacity, the U.S. firm has a huge advantage. So I just wanted to

Starting point is 00:19:56 point out like, look, it's really easy to stare at screens. But try and stick to your process, try to stick your research. One thing I've been doing is, I'll tell you that in a second, but try to see your process, try to stick your research. Keep turning over rocks because if you do that, you might, A, see better opportunities than are in your portfolio currently. And B, you might see really unique opportunities that have popped up because of the environment. And if you're turning over the rocks, you're more likely to see that in real time. And it's things that, you know, investors who are still on it or investors who aren't turning over rocks might not see in that real time. So I would just encourage you. And look, I ramble here because these are the

Starting point is 00:20:35 things I'm telling myself, I'm trying to do it to myself. So I've, you know, on Wednesday, when the markets go from down to up eight, I tell myself, hey, Andrew, okay, this is nice. It feels nice to see green on the screen for once. But let's not stare at the screen. That is an unproductive use of your time. Let's go try to turn over some more rocks. Let's try to find some companies that, you know, Chinese tariffs are going to, I don't know, are they at 400% now? If you're going to slap Chinese tariffs at 400% and 10% on everyone else in the world, maybe there's a company you can find that is actually going to be a big beneficiary because all of their competitors source from China and these guys have better sourcing

Starting point is 00:21:09 from Taiwan or domestically or whatever it is. So just keep turning over rocks. That's what I'm telling myself. That's what I'm trying to do, not steer at the screen, make sure everything I'm doing is kind of maximizing the opportunity. And then I think there was something else I was going to say, but I can't remember. Look, it's been a really rocky volatile month. Keep your heads about you.

Starting point is 00:21:33 Keep the process going. Oh, the other thing I tried to do is, look, maybe I'm too caught up in the moment and maybe stops or whipping too wildly to really research a company. The other thing I've been trying to do is like longer term projects, right? And I'll give you one example. step back and re-research, like reevalued my process for pipeline, like, hey, can this be improved? Like, how am I sourcing new ideas? Can this be improved? Or I look at my writings and my step over the year, I've been banging the drums on improving how you use AI in your research process and everything for

Starting point is 00:22:07 two years, basically since chat GPT kind of came out, I've been banging the drums on that. And I think now if you're just, hey, I can't research companies for some reason. Like, it's just too volatile. I'm just too lost in the market. Well, then you can say, hey, I'm going to spend some time on a longer-term project. And maybe I'm going to spend more time learning how to better incorporate chat, GPT, or AI, or whatever it is, into my process. How to better incorporate it into my portfolio process, my research process, whatever it is. And there's other examples. Hey, I've been meaning to learn how to, this is hypothetical, I've been meaning to learn how to code so I can build some custom scripts to, you know, better alert myself when certain key.

Starting point is 00:22:48 words or anything pop up. Maybe it's time to do that. Maybe there's a book on, I don't know, maybe you've been wanting to smarten up on bankruptcy code. Maybe you go read a book on bankruptcy code or do some case, some historical studies on bankruptcies and how those played out for investors so that the next time a bankruptcy pops up, you're better prepared and better equipped to go research that. But, you know, you don't have to just like read 10Ks all day. If you're having trouble looking at new companies, I think looking at new companies really good to see, you know, make sure your portfolio measures up against the opportunity costs elsewhere. But there are other things you can do longer-term projects, and that's the other thing.

Starting point is 00:23:21 For me, it's AI and figuring out new tools and new ways to use AI in my research process. I'll probably do a post on this at some point. But, you know, if 20 years ago, 30 years ago, you have been like, oh, I'm not going to use the internet. I've always used the library and snail mail. I'm not using email and Google. Well, you know, within weeks, you would have been behind people. And that kind of scales cumulatively, right?

Starting point is 00:23:46 if you don't use email and you adopt it two years later than people, then yeah, you can catch up to them a little bit, but your whole process is going to be kind of two years behind, and you'll catch up a little bit more because, like, the ground has been blazed, but you're always going to be a little bit behind the people who had naturally incorporated email, Google, whatever it is, into their process. With AI, like, if you're just sitting there saying, I refuse to use AI, I think it's so clear AI is such a useful tool. You're just going to be falling behind your investor friends. And yes, when you finally incorporate it, you're going to be able to, like, incorporate a little faster than the people who are trailblazers because the best practice will have been laid out. But it's, you know, if I use it for six months and then you try to catch up, well, I've got a big head start. And I've probably incorporated it better into my processes and understood it and know how to use some tricks better.

Starting point is 00:24:34 You're falling behind pretty quickly and the world's moving faster. So you fall behind just a little bit and that's a cumulative edge of I guess this last thing, you know, AI, past few years I've been talking about it. I still haven't had investors, like, really ping me with, investors or myself, really ping me with, like, ways better to use AI than, like, improving the prompts that you give it and the questions, obviously uploading some files to it, some of your internal files, and, like, we're in it on some of your ideas. But I haven't heard much better than that, always looking for new ways to incorporate, improve, use AI, because I just think it's such a revolutionary tools. And some of the stuff it does is just mind-blowing to me. I keep mentioning these busted biotechs. There was one busted biotech where I spent like a day and a half and three expert calls trying to get up to speed on one of their drugs

Starting point is 00:25:21 to see if there was any value there. And then I just type the drug into chat, GPT and say, hey, write a research report with me using deep research. And the deep research was better than the day and a half that I had spent on it. And I'm not a scientist or anything. But it was, it picked it up like that, 15 minutes, you know, just put in a good prompt, give it 15 minutes to run, come back, and boom, It was better than, it was really good.

Starting point is 00:25:44 It was really good. Anyway, look, it has been rocky. Stay safe out there. I've got a semi, very, I can't tell you. I just told you, hey, markets get rocky and you need to stick to your process. I've got a vacation coming up next week, working vacation, but going on vacation to Austin with the family. I can't tell you how poorly time that feels, but I'm going to try and take my own advice and, you know, keep things normal, work a little bit in the mornings and hang out with the family of the afternoon, but man,

Starting point is 00:26:14 it does not feel like a fun time to take that. And then I've got a work trip to Planet MicroCab in Vegas the week of the 20th. If you're out there, picking me up, love to see you and everything. But I'm really looking forward to those. That is my random ramblings for April 2025. I'm looking forward to the May 2025 random ramblings. May markets be in a better place than they were this month. And hopefully I'll have, still have some interesting things to talk about, as always, hit me up, Twitter, ex, DM, email, wherever you want to always have to chat, and we will go from there. Talk to you next month. Today's podcast is sponsored by DeLupa. Are you ready to cut through the noise in AI and discover

Starting point is 00:26:54 the real impact it's having in financial services? Join me alongside Thomas Lee, the CEO of Delupa on April 15th at 1 p.m. Eastern for an exclusive webinar where we'll dive deep into the future of AI tooling and finance. We've all heard the hype, but what's the truth behind the tech? We'll discuss how AI is transforming financial workflows and where it's actually delivering value. With Thomas' experience leading a fundamental data company that leverages AI, you'll get firsthand insights into what works and what doesn't in this space. Whether you're managing a hedge fund, analyzing financial data, or simply interested in how AI is shaping the future of finance, this webinar is for you.

Starting point is 00:27:29 Don't miss out on valuable insights from industry leaders. Register now at dilupa.com slash y-A-V webinar. That's the Lupa, D-A-O-O-O-P-A dot com slash Y-A-V webinar for the April 15th, 1 p.m. Eastern webinar and get ready to uncover the truth about AI and finance. A quick disclaimer, nothing on this podcast should be considered an investment advice. Guests or the hosts may have positions in any of the stocks mentioned during this podcast. Please do your own work and consult a financial advisor. Thanks.

Yet Another Value Podcast - Random Ramblings April 2025

There aren't comments yet for this episode. Click on any sentence in the transcript to leave a comment.